<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="65181"><DrugName>IMC-CS4</DrugName><DrugSynonyms><Name><Value>IMC-CS4</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CSF-1R mAb (cancer), Imclone/Eli Lilly</Value></Name><Name><Value>colony-stimulating factor receptor 1 antagonist (cancer), Imclone/Eli Lilly</Value></Name><Name><Value>CSF-R1 monocloncal antibody (cancer), Eli Lilly/Imclone</Value></Name><Name><Value>CS-7</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CSF-1R monoclonal antibody (cancer), Eli Lilly</Value></Name><Name><Value>LY-3022855</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17193">Imclone LLC</CompanyOriginator><CompaniesSecondary><Company id="17193">Imclone LLC</Company><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="65181" type="Drug"><TargetEntity id="744231" type="siDrug">IMC-CS4</TargetEntity></SourceEntity><SourceEntity id="17193" type="Company"><TargetEntity id="4295906769" type="organizationId">ImClone LLC</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"></TargetEntity><TargetEntity id="708" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3664" type="ciIndication"><TargetEntity id="10036909" type="MEDDRA"></TargetEntity><TargetEntity id="639" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00510" type="ciTarget"><TargetEntity id="174052253714363" type="siTarget">Macrophage colony-stimulating factor 1 receptor</TargetEntity><TargetEntity id="471" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="3257">Stage IV melanoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3664">Metastatic prostate cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="3154">CSF-1 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="51">Monoclonal antibody</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-02-12T11:24:43.000Z</LastModificationDate><ChangeDateLast>2018-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2009-12-17T12:25:27.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt; (through its acquisition of &lt;ulink linkID="17193" linkType="Company"&gt;Imclone&lt;/ulink&gt;) was developing IMC-CS4 (LY-3022855), the lead  from a  program of monoclonal antibodies targeting  colony-stimulating factor receptor 1(CSF-1R), for the potential iv treatment of  advanced solid tumors, including advanced melanoma [&lt;ulink linkID="1063318" linkType="Reference"&gt;1063318&lt;/ulink&gt;], [&lt;ulink linkID="1916518" linkType="Reference"&gt;1916518&lt;/ulink&gt;]. In June 2011, a phase I trial was initiated in patients with refractory solid tumors [&lt;ulink linkID="1202585" linkType="Reference"&gt;1202585&lt;/ulink&gt;]. In  May 2015, a phase I trial was  initiated in advanced breast and prostate cancer  [&lt;ulink linkID="1615601" linkType="Reference"&gt;1615601&lt;/ulink&gt;]. In June 2017, an investigator-initiated phase I/II trial in advanced melanoma began [&lt;ulink linkID="1916518" linkType="Reference"&gt;1916518&lt;/ulink&gt;]. The antibody was still listed on Eli Lilly's pipeline as in phase I development for cancer in July 2018 [&lt;ulink linkID="2058545" linkType="Reference"&gt;2058545&lt;/ulink&gt;]; however, by October 2018, development of IMC-CS4 had been discontinued [&lt;ulink linkID="2094936" linkType="Reference"&gt;2094936&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Advanced melanoma&lt;/subtitle&gt;In June 2017, the &lt;ulink linkID="15615" linkType="Company"&gt;Dana-Farber Cancer Institute&lt;/ulink&gt;, in collaboration with Eli Lilly, initiated an interventional, single group assigned, phase I/II trial (&lt;ulink linkID="293180" linkType="Protocol"&gt;NCT03101254&lt;/ulink&gt;; 17-030 )   in the US to assess  IMC-CS4 with BRAF/MEK inhibition in patients (expected n = 43) with advanced melanoma. In July 2017, the trial was expected to complete in  October 2023 [&lt;ulink linkID="1916518" linkType="Reference"&gt;1916518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I trials in advanced solid tumors&lt;/subtitle&gt;In March 2016, an open-label,  phase Ia/Ib trial   (&lt;ulink linkID="256616" linkType="Protocol"&gt;NCT02718911&lt;/ulink&gt;; 16348  I5F-MC-JSCC  2016-000427-11) of the drug in combination with &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt;  or &lt;ulink linkID="45562" linkType="Drug"&gt;tremelimumab&lt;/ulink&gt; in patients (expected n = 178) with advanced solid tumors, was to begin in May 2016. The study was to complete in November 2018. In July 2016, the trial was initiated  in the US, Europe and Israel. At that time, completion was expected in December 2018  [&lt;ulink linkID="1750606" linkType="Reference"&gt;1750606&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014,  an open-label, single-group assignment, non-randomized, phase I study (&lt;ulink linkID="213465" linkType="Protocol"&gt;NCT02265536&lt;/ulink&gt;; 15441, I5F-MC-JSCB)  was planned to be initiated to assess the immunomodulatory activity of IMC-CS4  in patients (expected n =  16) with advanced, refractory breast or prostate cancer by  December 2014 in the US.  In May 2015, the trial was initiated; it was completed in  October 2017 [&lt;ulink linkID="1615601" linkType="Reference"&gt;1615601&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a non-randomized, open-label, phase I study (&lt;ulink linkID="77060" linkType="Protocol"&gt;NCT01346358&lt;/ulink&gt;; 14311; CP24-1001) was initiated in patients with refractory solid tumors (expected n = 24) in the US, to assess the safety, pharmacokinetics and pharmacodynamics of IMC-CS4. In October 2011, trial completion was expected in December 2012  [&lt;ulink linkID="1202585" linkType="Reference"&gt;1202585&lt;/ulink&gt;]. In June 2017, clinical data from 35 patients were presented at the 53rd ASCO meeting in Chicago, IL. Stable disease and progressive disease were observed in 1 and 19 patients, respectively; and disease control rate was 3% (according to RECIST v1.1).  Pharmacokinetic profile of IMC-CS4 was consistent with IgG1 mAbs. Grade &amp;gt;/= 4 TEAEs were serious (6%), sudden death (3%), rhabdomyolysis (3%) and confusional state (3%). IMC-CS4 showed dose-dependent increase in serum CSF-1 levels as well as suppression of circulating non-classical monocytes (CD14[dim]CD16[bright]). Due to concern related to viability of 150 mg weekly dosing (grade 3 creatine kinase  elevation), 100 mg weekly was selected as the recommended phase II dose  [&lt;ulink linkID="1931733" linkType="Reference"&gt;1931733&lt;/ulink&gt;]. The trial was completed in May 2018 following enrollment of 72 patients [&lt;ulink linkID="1202585" linkType="Reference"&gt;1202585&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2016, preclinical data were presented using CS-7, an anti-mouse-CSF-1R surrogate antibody, at the 31st SITC Annual Meeting in National Harbor, MD. In approximately 60% of mice, CSF-1R blockade + anti-programmed death-ligand 1 enhanced the control of tumor growth and displayed a late combinatorial effect which led to complete regressions. Immunologic memory was developed by mice that achieved complete regressions and resisted re-challenge over 60 days after cessation of therapy [&lt;ulink linkID="1883943" linkType="Reference"&gt;1883943&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, preclinical data on CS-7 were presented at the 25th International AACR-NCI-EORTC Symposium in Boston, MA. Both CSF-1 and IL-34 binding to mouse CSF-1R were inhibited by CS-7. Monocyte proliferation and macrophage differentiation were prevented with CS-7 with IC50 values of 0.1 and 0.75 nM, respectively.Tumor-associated macrophages were decreased markedly in murine models of breast cancer using CSF-1-secreting MDA-MB-231, Hcc1954, 4T1 or EMT6 tumor cells. However, there was limited or no decrease in tumor xenografts with CSF-1 non-secreting breast tumor cell lines JimT1 and MCF-7. CS-7 inhibited tumor growth in prostate models, DU145 tumor cell line xenografts (CSF-1-secreting) but not PC3 (CSF-1 non-secreting) [&lt;ulink linkID="1491153" linkType="Reference"&gt;1491153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, preclinical data on CS-7 were presented at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. CS-7  inhibited tumor growth in a MDA-MB-231-LP-OS-PT breast tumor xenograft model and a DU145 prostate xenograft model. In a HCC1954 breast cancer model, the combination of CS-7 and Herceptin was synergistic and more efficacious than monotherapy of either compound [&lt;ulink linkID="1240599" linkType="Reference"&gt;1240599&lt;/ulink&gt;]. In April 2012, similar data were presented at the 103rd AACR meeting in Chicago, IL [&lt;ulink linkID="1275523" linkType="Reference"&gt;1275523&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3664">Metastatic prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-30T00:00:00.000Z</StatusDate><Source id="2094936" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-30T00:00:00.000Z</StatusDate><Source id="2094936" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-30T00:00:00.000Z</StatusDate><Source id="2094936" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-30T00:00:00.000Z</StatusDate><Source id="2094936" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-30T00:00:00.000Z</StatusDate><Source id="2094936" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-30T00:00:00.000Z</StatusDate><Source id="2094936" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-06T00:00:00.000Z</StatusDate><Source id="1916518" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-12T00:00:00.000Z</StatusDate><Source id="1750606" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-12T00:00:00.000Z</StatusDate><Source id="1750606" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-20T00:00:00.000Z</StatusDate><Source id="1202585" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-31T00:00:00.000Z</StatusDate><Source id="1615601" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3664">Metastatic prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-31T00:00:00.000Z</StatusDate><Source id="1615601" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17193">Imclone LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-10T00:00:00.000Z</StatusDate><Source id="1063318" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00510"><Name>CSF-1</Name><SwissprotNumbers><Swissprot>P07333</Swissprot><Swissprot>P09581</Swissprot><Swissprot>P13369</Swissprot><Swissprot>Q00495</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3652501" number="WO-2017091429" title="Combination therapy for cancer"></PatentFamily><PatentFamily id="4145835" number="WO-2018144334" title="Dosing regimen for anti-CSF-1R antibody"></PatentFamily><PatentFamily id="524090" number="WO-2011123381" title="Antibodies against CSF-1R"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>